Group 1 - Savara Inc. is presenting data on its investigational treatment, molgramostim, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) [1][3] - The presentation highlights positive results from the Phase 3 IMPALA-2 trial, demonstrating molgramostim's ability to enhance lung diffusing capacity [2] - Savara is a clinical-stage biopharmaceutical company focused on therapies for rare respiratory diseases, with molgramostim being its lead product candidate [3]